<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9919">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895205</url>
  </required_header>
  <id_info>
    <org_study_id>PP-02</org_study_id>
    <nct_id>NCT01895205</nct_id>
  </id_info>
  <brief_title>Treatment of Women After Severe Postpartum Haemorrhage</brief_title>
  <acronym>PP-02</acronym>
  <official_title>A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Red Blood Cell Transfusion in Women With Severe Postpartum Iron Deficiency Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioStata</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to get explorative information about IV high single
      dose infusion of iron isomaltoside 1000 compared to RBC transfusion in the treatment of
      severe PP-IDA evaluated as physical fatigue
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Physical Fatigue</measure>
    <time_frame>From exposure to 12 weeks post-exposure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb concentration</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-ferritin</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue symptoms</measure>
    <time_frame>from baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum depression</measure>
    <time_frame>From week 1 to 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding</measure>
    <time_frame>From exposure to 12 weeks post-exposure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reactions (ADRs)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-iron</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in p-transferrin</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transferrin saturation (TSAT)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in reticulocyte count</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change mean reticulocyte haemoglobin content (CHr)</measure>
    <time_frame>From baseline to day 1, 2, 3, 4, 5, 6 and 7, week 3, 8 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in anaemia symptoms</measure>
    <time_frame>From Baseline to week 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in gastrointestinal symptoms</measure>
    <time_frame>From Baseline to week 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red blood cell transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allogenic RBC transfusion is dosed to trigger Hb:
Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC
Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron isomaltoside 1000</intervention_name>
    <arm_group_label>Iron isomaltoside 1000</arm_group_label>
    <other_name>Monofer®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Red blood cell transfusion</intervention_name>
    <arm_group_label>Red blood cell transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PPH &gt; 1000 mL

          2. Hb ≥ 5.5 and ≤ 8.0 g/dL (≥ 3.5 and ≤ 5.0 mmol/L)

          3. Willingness to participate and signed the informed consent form

        Exclusion Criteria:

          1. Women aged &lt; 18 years

          2. Multiple births

          3. Peripartum RBC transfusion

          4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and
             haemosiderosis)

          5. Known hypersensitivity to parenteral iron or any excipients in the investigational
             drug products

          6. Women with a history of active asthma within the last 5 years or a history of
             multiple allergies

          7. Known decompensated liver cirrhosis and active hepatitis

          8. Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syndrome
             (defined according to &quot;Dansk Selskab for Obstetrik og Gynækologi guidelines&quot;)

          9. Active acute infection assessed by clinical judgement

         10. Rheumatoid arthritis with symptoms or signs of active joint inflammation

         11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia
             (known haematologic disorder other than iron deficiency)

         12. Not able to read, speak and understand the Danish language

         13. Participation in any other clinical study where the study drug has not passed 5
             half-lives prior to the baseline

         14. Any other medical condition that, in the opinion of Investigator, may cause the
             patient to be unsuitable for completion of the study or place the patient at
             potential risk from being in the study. For example, a malignancy, uncontrolled
             hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lars Lykke Thomsen</last_name>
    <phone>+45 59 48 59 59</phone>
    <email>LLT@Pharmacosmos.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
